Curriculum Vitae

Personal information

Janusz Szyndler

Work experience

1. Employer: Medical University of Warsaw, Department of Clinical and Experimental Pharmacology
   - Start date: 032000
   - End date:
   - Position: Assistant Professor
   - Activities: Experimental research, Education
   - Country: Poland
2. Employer: Institute of Psychiatry and Neurology, First Department of Neurology
   - Start date: 072000
   - End date: 082007
   - Position: Assistant
   - Activities: Medical care
   - Country: Poland

Education and training

1. Subject: Institute of Psychiatry and Neurology
   - Start date: 072000
   - End date: 022006
   - Qualification: Specialist in neurology
   - Organisation: Neurology training
   - Country: Poland
2. Subject: Medical University of Warsaw
   - Start date: 012002
   - End date: 032005
   - Qualification: PhD
   - Organisation: Experimental epilepsy
   - Country: Poland
3. Subject: Medical University of Warsaw
   - Start date: 101992
   - End date: 101998
   - Qualification: MD
   - Organisation: General Medicine
   - Country: Poland

Additional information

Publications

I am the author or co-author of 90 publications published in journals with an impact factor (IF). A list of 10 selected recent publications:

1. Chmielewska N, Szyndler J. Innovations in epilepsy treatment: pharmacological strategies and machine learning applications. Neurol Neurochir Pol. 2025 Mar 27. doi: 10.5603/pjnns.103446. Epub ahead of print. PMID: 40145575.
2. Wisłowska-Stanek A, Turzyńska D, Sobolewska A, Kołosowska K, Szyndler J, Skórzewska A, Maciejak P. The effect of valproate on the amino acids, monoamines, and kynurenic acid concentrations in brain structures involved in epileptogenesis in the pentylenetetrazol-kindled rats. Pharmacol Rep. 2024 Apr;76(2):348-367.
3. Chmielewska N, Szyndler J. Intranasal administration of antiseizure medications in chronic and emergency treatment: Hopes and challenges. Seizure. 2024 Feb;115:62-67.
4. Chmielewska N, Szyndler J. Targeting CD20 in multiple sclerosis - review of current treatment strategies. Neurol Neurochir Pol. 2023;57(3):235-242.
5. Chmielewska N, Wawer A, Wicik Z, Osuch B, Maciejak P, Szyndler J. miR-9a-5p expression is decreased in the hippocampus of rats resistant to lamotrigine: A behavioural, molecular and bioinformatics assessment. Neuropharmacology. 2023 Apr 1;227:109425.
6. Chmielewska N, Wawer A, Osuch B, Maciejak P, Szyndler J. mTOR and HDAC2 are simultaneously activated during electrically induced kindling of seizures. Epilepsy Res. 2022 Sep;185:106991.
7. Osuch B, Kołosowska K, Chmielewska N, Turzyńska D, Sobolewska A, Szyndler J, Maciejak P. Increased Hippocampal Afterdischarge Threshold in Ketogenic Diet is Accompanied by Enhanced Kynurenine Pathway Activity. Neurochem Res. 2022 Jul;47(7):2109_2122.
8. Pogoda A, Chmielewska N, Maciejak P, Szyndler J. Transcriptional dysregulation in Huntington's Disease. The role in pathogenesis and potency for pharmacological targeting. Curr Med Chem. 2020 Jul 5.
9. Skórzewska A, Lehner M, Wisłowska_Stanek A, Turzyńska D, Sobolewska A, Krząścik P, Szyndler J, Maciejak P, Chmielewska N, Kołosowska K, Płaźnik A. Individual susceptibility or resistance to posttraumatic stress disorder_like behaviours. Behav Brain Res. 2020 May 27;386:112591.
10. Chmielewska N, Wawer A, Maciejak P, Turzyńska D, Sobolewska A, Skórzewska A, Osuch B, Płaźnik A, Szyndler J. The role of REST/NRSF, TrkB and BDNF in neurobiological mechanisms of different susceptibility to seizure in a PTZ model of epilepsy. Brain Res Bull. 2020 May;158:108_115.

Projects

1. Since February 2025, principal investigator of the project entitled *"Assessment of the role of miRNA as a peripheral biomarker of drug resistance in epilepsy using biosensors for electrochemical detection"*, awarded funding under the "OPUS 27" call of the National Science Centre, project number 2024/53/B/NZ5/03371. The project is being carried out as part of a consortium composed of the Medical University of Warsaw, the Institute of Psychiatry and Neurology, and the Warsaw University of Technology. The planned duration of the project is 4 years (until February 2029).

Memberships

- Polish Pharmacological Society - member

- Polish Society of Clinical Pharmacology and Therapy - member

Other Relevant Information